PT - JOURNAL ARTICLE AU - Lin, Dachuan AU - Liu, Lei AU - Zhang, Mingxia AU - Hu, Yunlong AU - Yang, Qianting AU - Guo, Jiubiao AU - Dai, Youchao AU - Xu, Yuzhong AU - Cai, Yi AU - Chen, Xinchun AU - Huang, Kaisong AU - Zhang, Zheng TI - Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak AID - 10.1101/2020.03.27.20045153 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.27.20045153 4099 - http://medrxiv.org/content/early/2020/03/30/2020.03.27.20045153.short 4100 - http://medrxiv.org/content/early/2020/03/30/2020.03.27.20045153.full AB - The ongoing SARS-CoV-2 outbreak has killed over twenty-one thousand and sickened over four hundred thousand people worldwide, posing a great challenge to global public health. A sensitive and accurate diagnosis method will substantially help to control disease expansion. Here, we developed a chemiluminescence-immunoassay method based on the recombinant nucleocapsid antigen and the magnetic beads for diagnosis of SARS-CoV-2 infections and surveillance of antibody changing pattern.Serums from 29 healthy individuals, 51 tuberculosis patients, and 79 SARS-CoV-2 confirmed patients were employed to evaluate the performance of this approach. Compared to the IgM testing, the IgG testing was more reliable in which it identified 65 SARS-CoV-2 infections from the 79 confirmed patients and only two false-positive cases from the 80 control group with a sensitivity and specificity reaching 82.28% and 97.5%, respectively. However, only a slight difference (not statistically significant) in the detected cases of SARS-CoV-2 infections was observed between the IgM and IgG testing manner in patients at a different time of onset of disease. A performance comparison between an ELISA kit using the same nucleocapsid antigen and our chemiluminescence method was undertaken. The same false-positive cases were seen in both methods from the paired control group, while ELISA kit can only detect half of the SARS-CoV-2 infections from paired SARS-CoV-2 confirmed patients group than that of the chemiluminescence method, indicating a higher performance for the chemiluminescence-immunoassay approach. Together, our studies provide a useful and valuable serological testing tool for the diagnosis of SARS-CoV-2 infections in the community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by Guangdong Provincial Science and Technology Program (No. 2019b030301009), the National Natural Science Funds of China (81802060), the start-up funding of Shenzhen University and the National Science and Technology Major Project (2017ZX10201301).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data referred to in the manuscript has been included in the main text and supplementary files.